Cellectis (CLLS)

• Market cap: $361M
• 1 day: 2.57%
• 5 days: 2.87%
• 1 month: -6.02%
• 3 months: -15.73%
• 6 months: -11.14%
• Year to date: -25.21%
• 1 year: 191.87%
• 5 years: -80.76%
• 10 years: -87.22%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 229